Left atrial appendage closure with the watchman device reduces atrial fibrillation management costs
Aims To report hospitalization costs of patients with non-valvular atrial fibrillation (AF) submitted to percutaneous left atrial appendage closure (LAAC) with the Watchman device. Methods Pre- and post-procedural hospitalization AF-related costs were calculated using the DRG system (diagnosis-relat...
Saved in:
Published in | Clinical research in cardiology Vol. 111; no. 1; pp. 105 - 113 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.01.2022
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
ISSN | 1861-0684 1861-0692 1861-0692 |
DOI | 10.1007/s00392-021-01943-7 |
Cover
Abstract | Aims
To report hospitalization costs of patients with non-valvular atrial fibrillation (AF) submitted to percutaneous left atrial appendage closure (LAAC) with the Watchman device.
Methods
Pre- and post-procedural hospitalization AF-related costs were calculated using the DRG system (diagnosis-related groups) and compared.
Results
Between 2012 and 2016, 677 non-valvular AF patients underwent LAAC. Median time from first cardiac hospitalization to LAAC was 5.9 years (IQR 1.6–9.1) and median follow-up after LAAC was 4.8 years (IQR 3.6–5.6). LAAC mortality was 1.3% and follow-up mortality 16.9%. Median pre-LAAC hospitalization cost was € 17,867 (IQR € 7512–35,08) and post-LAAC € 8772 (IQR € 1183–25,159) (
p
< 0.0001). Annualized cost pre-LAAC was 3773 € (IQR € 1644–8,493) and post-LAAC 2,001 € (IQR € 260–6913) (
p
< 0.0001). Follow-up survivors had significantly lower post-LAAC costs (
p
< 0.0001) and after a survival cut-off time of 4.6 years LAAC procedural and post-procedural hospitalization costs achieved parity with pre-LACC costs (AUC 0.64;
p
= 0.02). CHA2DS2-VASc score (
B
= 0.04;
p
= 0.02; 95% CI 0.006–0.08), and HAS-BLED score (
B
= 0.08;
p
= 0.004; 95% CI 0.02–0.14) were independent determinants for annualized hospitalization costs post-LAAC. At Cox-regression analysis the DRG mean clinical complexity level (CCL) was the only independent determinant for follow-up mortality (OR = 2.2;
p
< 0.0001; 95% CI 1.6–2.8) with a cut-off value of 2.25 to predict follow-up mortality (AUC 0.72;
p
< 0.0001; Spec. 70%; Sens. 70%).
Conclusion
Hospitalization costs pre-LAAC are consistent, and after LAAC, they are significantly reduced. Costs seem related to the patient's risk profile at the time of the procedure. With the increase in post-LAAC survival time, the procedure becomes economically more profitable.
Graphic abstract |
---|---|
AbstractList | To report hospitalization costs of patients with non-valvular atrial fibrillation (AF) submitted to percutaneous left atrial appendage closure (LAAC) with the Watchman device.AIMSTo report hospitalization costs of patients with non-valvular atrial fibrillation (AF) submitted to percutaneous left atrial appendage closure (LAAC) with the Watchman device.Pre- and post-procedural hospitalization AF-related costs were calculated using the DRG system (diagnosis-related groups) and compared.METHODSPre- and post-procedural hospitalization AF-related costs were calculated using the DRG system (diagnosis-related groups) and compared.Between 2012 and 2016, 677 non-valvular AF patients underwent LAAC. Median time from first cardiac hospitalization to LAAC was 5.9 years (IQR 1.6-9.1) and median follow-up after LAAC was 4.8 years (IQR 3.6-5.6). LAAC mortality was 1.3% and follow-up mortality 16.9%. Median pre-LAAC hospitalization cost was € 17,867 (IQR € 7512-35,08) and post-LAAC € 8772 (IQR € 1183-25,159) (p < 0.0001). Annualized cost pre-LAAC was 3773 € (IQR € 1644-8,493) and post-LAAC 2,001 € (IQR € 260-6913) (p < 0.0001). Follow-up survivors had significantly lower post-LAAC costs (p < 0.0001) and after a survival cut-off time of 4.6 years LAAC procedural and post-procedural hospitalization costs achieved parity with pre-LACC costs (AUC 0.64; p = 0.02). CHA2DS2-VASc score (B = 0.04; p = 0.02; 95% CI 0.006-0.08), and HAS-BLED score (B = 0.08; p = 0.004; 95% CI 0.02-0.14) were independent determinants for annualized hospitalization costs post-LAAC. At Cox-regression analysis the DRG mean clinical complexity level (CCL) was the only independent determinant for follow-up mortality (OR = 2.2; p < 0.0001; 95% CI 1.6-2.8) with a cut-off value of 2.25 to predict follow-up mortality (AUC 0.72; p < 0.0001; Spec. 70%; Sens. 70%).RESULTSBetween 2012 and 2016, 677 non-valvular AF patients underwent LAAC. Median time from first cardiac hospitalization to LAAC was 5.9 years (IQR 1.6-9.1) and median follow-up after LAAC was 4.8 years (IQR 3.6-5.6). LAAC mortality was 1.3% and follow-up mortality 16.9%. Median pre-LAAC hospitalization cost was € 17,867 (IQR € 7512-35,08) and post-LAAC € 8772 (IQR € 1183-25,159) (p < 0.0001). Annualized cost pre-LAAC was 3773 € (IQR € 1644-8,493) and post-LAAC 2,001 € (IQR € 260-6913) (p < 0.0001). Follow-up survivors had significantly lower post-LAAC costs (p < 0.0001) and after a survival cut-off time of 4.6 years LAAC procedural and post-procedural hospitalization costs achieved parity with pre-LACC costs (AUC 0.64; p = 0.02). CHA2DS2-VASc score (B = 0.04; p = 0.02; 95% CI 0.006-0.08), and HAS-BLED score (B = 0.08; p = 0.004; 95% CI 0.02-0.14) were independent determinants for annualized hospitalization costs post-LAAC. At Cox-regression analysis the DRG mean clinical complexity level (CCL) was the only independent determinant for follow-up mortality (OR = 2.2; p < 0.0001; 95% CI 1.6-2.8) with a cut-off value of 2.25 to predict follow-up mortality (AUC 0.72; p < 0.0001; Spec. 70%; Sens. 70%).Hospitalization costs pre-LAAC are consistent, and after LAAC, they are significantly reduced. Costs seem related to the patient's risk profile at the time of the procedure. With the increase in post-LAAC survival time, the procedure becomes economically more profitable.CONCLUSIONHospitalization costs pre-LAAC are consistent, and after LAAC, they are significantly reduced. Costs seem related to the patient's risk profile at the time of the procedure. With the increase in post-LAAC survival time, the procedure becomes economically more profitable. Aims To report hospitalization costs of patients with non-valvular atrial fibrillation (AF) submitted to percutaneous left atrial appendage closure (LAAC) with the Watchman device. Methods Pre- and post-procedural hospitalization AF-related costs were calculated using the DRG system (diagnosis-related groups) and compared. Results Between 2012 and 2016, 677 non-valvular AF patients underwent LAAC. Median time from first cardiac hospitalization to LAAC was 5.9 years (IQR 1.6–9.1) and median follow-up after LAAC was 4.8 years (IQR 3.6–5.6). LAAC mortality was 1.3% and follow-up mortality 16.9%. Median pre-LAAC hospitalization cost was € 17,867 (IQR € 7512–35,08) and post-LAAC € 8772 (IQR € 1183–25,159) ( p < 0.0001). Annualized cost pre-LAAC was 3773 € (IQR € 1644–8,493) and post-LAAC 2,001 € (IQR € 260–6913) ( p < 0.0001). Follow-up survivors had significantly lower post-LAAC costs ( p < 0.0001) and after a survival cut-off time of 4.6 years LAAC procedural and post-procedural hospitalization costs achieved parity with pre-LACC costs (AUC 0.64; p = 0.02). CHA2DS2-VASc score ( B = 0.04; p = 0.02; 95% CI 0.006–0.08), and HAS-BLED score ( B = 0.08; p = 0.004; 95% CI 0.02–0.14) were independent determinants for annualized hospitalization costs post-LAAC. At Cox-regression analysis the DRG mean clinical complexity level (CCL) was the only independent determinant for follow-up mortality (OR = 2.2; p < 0.0001; 95% CI 1.6–2.8) with a cut-off value of 2.25 to predict follow-up mortality (AUC 0.72; p < 0.0001; Spec. 70%; Sens. 70%). Conclusion Hospitalization costs pre-LAAC are consistent, and after LAAC, they are significantly reduced. Costs seem related to the patient's risk profile at the time of the procedure. With the increase in post-LAAC survival time, the procedure becomes economically more profitable. Graphic abstract AimsTo report hospitalization costs of patients with non-valvular atrial fibrillation (AF) submitted to percutaneous left atrial appendage closure (LAAC) with the Watchman device.MethodsPre- and post-procedural hospitalization AF-related costs were calculated using the DRG system (diagnosis-related groups) and compared.ResultsBetween 2012 and 2016, 677 non-valvular AF patients underwent LAAC. Median time from first cardiac hospitalization to LAAC was 5.9 years (IQR 1.6–9.1) and median follow-up after LAAC was 4.8 years (IQR 3.6–5.6). LAAC mortality was 1.3% and follow-up mortality 16.9%. Median pre-LAAC hospitalization cost was € 17,867 (IQR € 7512–35,08) and post-LAAC € 8772 (IQR € 1183–25,159) (p < 0.0001). Annualized cost pre-LAAC was 3773 € (IQR € 1644–8,493) and post-LAAC 2,001 € (IQR € 260–6913) (p < 0.0001). Follow-up survivors had significantly lower post-LAAC costs (p < 0.0001) and after a survival cut-off time of 4.6 years LAAC procedural and post-procedural hospitalization costs achieved parity with pre-LACC costs (AUC 0.64; p = 0.02). CHA2DS2-VASc score (B = 0.04; p = 0.02; 95% CI 0.006–0.08), and HAS-BLED score (B = 0.08; p = 0.004; 95% CI 0.02–0.14) were independent determinants for annualized hospitalization costs post-LAAC. At Cox-regression analysis the DRG mean clinical complexity level (CCL) was the only independent determinant for follow-up mortality (OR = 2.2; p < 0.0001; 95% CI 1.6–2.8) with a cut-off value of 2.25 to predict follow-up mortality (AUC 0.72; p < 0.0001; Spec. 70%; Sens. 70%).ConclusionHospitalization costs pre-LAAC are consistent, and after LAAC, they are significantly reduced. Costs seem related to the patient's risk profile at the time of the procedure. With the increase in post-LAAC survival time, the procedure becomes economically more profitable.Graphic abstract To report hospitalization costs of patients with non-valvular atrial fibrillation (AF) submitted to percutaneous left atrial appendage closure (LAAC) with the Watchman device. Pre- and post-procedural hospitalization AF-related costs were calculated using the DRG system (diagnosis-related groups) and compared. Between 2012 and 2016, 677 non-valvular AF patients underwent LAAC. Median time from first cardiac hospitalization to LAAC was 5.9 years (IQR 1.6-9.1) and median follow-up after LAAC was 4.8 years (IQR 3.6-5.6). LAAC mortality was 1.3% and follow-up mortality 16.9%. Median pre-LAAC hospitalization cost was € 17,867 (IQR € 7512-35,08) and post-LAAC € 8772 (IQR € 1183-25,159) (p < 0.0001). Annualized cost pre-LAAC was 3773 € (IQR € 1644-8,493) and post-LAAC 2,001 € (IQR € 260-6913) (p < 0.0001). Follow-up survivors had significantly lower post-LAAC costs (p < 0.0001) and after a survival cut-off time of 4.6 years LAAC procedural and post-procedural hospitalization costs achieved parity with pre-LACC costs (AUC 0.64; p = 0.02). CHA2DS2-VASc score (B = 0.04; p = 0.02; 95% CI 0.006-0.08), and HAS-BLED score (B = 0.08; p = 0.004; 95% CI 0.02-0.14) were independent determinants for annualized hospitalization costs post-LAAC. At Cox-regression analysis the DRG mean clinical complexity level (CCL) was the only independent determinant for follow-up mortality (OR = 2.2; p < 0.0001; 95% CI 1.6-2.8) with a cut-off value of 2.25 to predict follow-up mortality (AUC 0.72; p < 0.0001; Spec. 70%; Sens. 70%). Hospitalization costs pre-LAAC are consistent, and after LAAC, they are significantly reduced. Costs seem related to the patient's risk profile at the time of the procedure. With the increase in post-LAAC survival time, the procedure becomes economically more profitable. |
Author | Arslan, Fatih Safak, Erdal Ince, Hüseyin Weber, Denise Kugler, Joachim Behrens, Steffen D´Ancona, Giuseppe Darius, Harald Zohlenhöfer-Momm, Dietlind Ortak, Jasmin Kische, Stephan |
Author_xml | – sequence: 1 givenname: Giuseppe orcidid: 0000-0002-4004-4521 surname: D´Ancona fullname: D´Ancona, Giuseppe email: rgea@hotmail.com organization: Department of Cardiology, Vivantes Klinikum Am Urban and Im Friedrichshain, Rostock University – sequence: 2 givenname: Erdal surname: Safak fullname: Safak, Erdal organization: Department of Cardiology, Vivantes Klinikum Am Urban and Im Friedrichshain, Rostock University – sequence: 3 givenname: Denise surname: Weber fullname: Weber, Denise organization: Department of Cardiology, Vivantes Klinikum Am Urban and Im Friedrichshain, Rostock University – sequence: 4 givenname: Fatih surname: Arslan fullname: Arslan, Fatih organization: Department of Cardiology, Vivantes Klinikum Am Urban and Im Friedrichshain, Rostock University – sequence: 5 givenname: Stephan surname: Kische fullname: Kische, Stephan organization: Department of Cardiology, Vivantes Klinikum Am Urban and Im Friedrichshain, Rostock University – sequence: 6 givenname: Harald surname: Darius fullname: Darius, Harald organization: Department of Cardiology, Vivantes Klinikum Neukölln – sequence: 7 givenname: Steffen surname: Behrens fullname: Behrens, Steffen organization: Department of Cardiology, Vivantes Klinikum Humboldt – sequence: 8 givenname: Dietlind surname: Zohlenhöfer-Momm fullname: Zohlenhöfer-Momm, Dietlind organization: Department of Cardiology, Vivantes Klinikum Wenckebach – sequence: 9 givenname: Jasmin surname: Ortak fullname: Ortak, Jasmin organization: Department of Cardiology, Vivantes Klinikum Am Urban and Im Friedrichshain, Rostock University – sequence: 10 givenname: Joachim surname: Kugler fullname: Kugler, Joachim organization: University of Applied Sciences Neubrandenburg – sequence: 11 givenname: Hüseyin surname: Ince fullname: Ince, Hüseyin organization: Department of Cardiology, Vivantes Klinikum Am Urban and Im Friedrichshain, Rostock University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34652527$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kc1u3SAQRlGUKH_tC3RRIXWTjZsBGzDLKmrTSlfqJlkjDONcIhvfAm7Vty_JTVIpi6wYpHNmRvOdkcO4RCTkA4PPDEBdZoBW8wY4a4Dprm3UATllvaxfqfnhS913J-Qs53sAwaDtjslJ20nBBVenxG1wLNSWFOxE7W6H0ds7pG5a8pqQ_gllS8u2Fra47Wwj9fg7OKQJ_eowP5tjGFKYJlvCEmnFao8ZY6FuySW_I0ejnTK-f3rPye23rzdX35vNz-sfV182jWuVKI2SWgnUguEwCsul8hqR6db3qJmUIIB7NwzcegtCCzl6Bgr8qEampBS2PScX-767tPxaMRczh-ywrhVxWbPhouc9qF5DRT-9Qu-XNcW6neGSgwbZaVapj0_UOszozS6F2aa_5vl8FeB7wKUl54TjC8LAPGRk9hmZmpF5zMg8SP0ryYXyeLmSbJjeVtu9muuceIfp_9pvWP8AChGlYA |
CitedBy_id | crossref_primary_10_1002_clc_24122 crossref_primary_10_1016_j_ijcard_2021_09_052 crossref_primary_10_1007_s12471_022_01675_x crossref_primary_10_1007_s00392_023_02299_w |
Cites_doi | 10.1161/01.STR.22.8.983 10.1093/eurheartj/ehaa612 10.1161/CIRCEP.115.003407 10.1016/j.cjca.2016.02.056 10.1016/j.jacc.2019.01.011 10.1016/j.jacc.2015.09.084 10.1001/jama.285.18.2370 10.1177/0272989X15593083 10.1186/s12872-016-0351-y 10.1007/s40258-018-0429-z 10.1093/europace/euv412 10.1161/CIRCULATIONAHA.112.000920 |
ContentType | Journal Article |
Copyright | Springer-Verlag GmbH Germany, part of Springer Nature 2021 2021. Springer-Verlag GmbH Germany, part of Springer Nature. Springer-Verlag GmbH Germany, part of Springer Nature 2021. |
Copyright_xml | – notice: Springer-Verlag GmbH Germany, part of Springer Nature 2021 – notice: 2021. Springer-Verlag GmbH Germany, part of Springer Nature. – notice: Springer-Verlag GmbH Germany, part of Springer Nature 2021. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8AO 8FD 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FR3 FYUFA GHDGH K9. M0S M1P M7Z P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 |
DOI | 10.1007/s00392-021-01943-7 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) ProQuest - Health & Medical Complete保健、医学与药学数据库 ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection PML(ProQuest Medical Library) Biochemistry Abstracts 1 Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Technology Research Database ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Biochemistry Abstracts 1 Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic Technology Research Database MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1861-0692 |
EndPage | 113 |
ExternalDocumentID | 34652527 10_1007_s00392_021_01943_7 |
Genre | Journal Article |
GeographicLocations | Germany |
GeographicLocations_xml | – name: Germany |
GroupedDBID | --- -5E -5G -BR -EM -Y2 -~C .VR 06C 06D 0R~ 0VY 1N0 203 29B 29~ 2J2 2JN 2JY 2KG 2LR 2P1 2VQ 2~H 30V 3V. 4.4 406 408 409 40D 40E 53G 5GY 5VS 67Z 6NX 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHXU ACIWK ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACSNA ACZOJ ADBBV ADHIR ADINQ ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFKRA AFLOW AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BDATZ BENPR BGNMA BPHCQ BSONS BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ IJ- IKXTQ IMOTQ IWAJR IXC IXD IXE IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KPH LLZTM M1P M4Y MA- N2Q N9A NB0 NPVJJ NQJWS NU0 O9- O93 O9I O9J OAM P9S PF0 PQQKQ PROAC PSQYO PT4 Q2X QOR QOS R89 R9I ROL RSV S16 S1Z S27 S37 S3B SAP SDH SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 TSG TSK TSV TT1 TUC U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 YLTOR Z45 Z7U Z81 Z82 Z83 Z87 ZMTXR ZOVNA ~KM AAPKM AAYXX ABBRH ABDBE ABFSG ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM 7XB 8FD 8FK ABRTQ FR3 K9. M7Z P64 PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 PUEGO |
ID | FETCH-LOGICAL-c375t-76975e951ebf5a267d9ee193d8e91660502dcbb2ada05956fd1070df7f17665a3 |
IEDL.DBID | BENPR |
ISSN | 1861-0684 1861-0692 |
IngestDate | Thu Sep 04 19:07:37 EDT 2025 Fri Jul 25 19:52:24 EDT 2025 Thu Apr 03 07:04:33 EDT 2025 Tue Jul 01 03:31:07 EDT 2025 Thu Apr 24 22:58:35 EDT 2025 Fri Feb 21 02:46:27 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Occlusion Appendage Costs Fibrillation Percutaneous Atrial Factors DRG Risk |
Language | English |
License | 2021. Springer-Verlag GmbH Germany, part of Springer Nature. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c375t-76975e951ebf5a267d9ee193d8e91660502dcbb2ada05956fd1070df7f17665a3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0002-4004-4521 |
PMID | 34652527 |
PQID | 2620906491 |
PQPubID | 326353 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_2582807890 proquest_journals_2620906491 pubmed_primary_34652527 crossref_primary_10_1007_s00392_021_01943_7 crossref_citationtrail_10_1007_s00392_021_01943_7 springer_journals_10_1007_s00392_021_01943_7 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20220100 2022-01-00 2022-Jan 20220101 |
PublicationDateYYYYMMDD | 2022-01-01 |
PublicationDate_xml | – month: 1 year: 2022 text: 20220100 |
PublicationDecade | 2020 |
PublicationPlace | Berlin/Heidelberg |
PublicationPlace_xml | – name: Berlin/Heidelberg – name: Germany – name: Heidelberg |
PublicationTitle | Clinical research in cardiology |
PublicationTitleAbbrev | Clin Res Cardiol |
PublicationTitleAlternate | Clin Res Cardiol |
PublicationYear | 2022 |
Publisher | Springer Berlin Heidelberg Springer Nature B.V |
Publisher_xml | – name: Springer Berlin Heidelberg – name: Springer Nature B.V |
References | Saw, Bennell, Singh, Wijeysundera (CR12) 2016; 32 Go, Hylek, Philips, Chang, Henault, Selby, Singer (CR1) 2001; 285 Wolf, Abbott, Kannel (CR2) 1991; 22 January, Wann, Calkins, Chen, Cigarroa, Cleveland, Ellinor, Ezekowitz, Field, Furie, Heidenreich, Murray, Shea, Tracy (CR4) 2019; 74 Singh, Micieli, Wijeysundera (CR8) 2013; 127 Nédellec, Pineau, Prognon, Martelli (CR5) 2018; 16 Micieli, Wijeysundera, Qiu, Atzema, Singh (CR6) 2016; 36 Reddy, Akehurst, Armstrong, Amorosi, Brereton, Hertz, Holmes (CR7) 2016; 18 Lee, Tsai, Chow, Yan, Kaya, Park, Lam (CR9) 2016; 16 Hindricks, Potpara, Dagres, Arbelo, Bax, Blomström-Lundqvist, Boriani, Castella, Dan, Dilaveris, Fauchier, Filippatos, Kalman, La Meir, Lane, Lebeau, Lettino, Lip, Pinto, Thomas, Valgimigli, Van Gelder, Van Putte, Watkins (CR3) 2020; 42 Reddy, Akehurst, Armstrong, Amorosi, Beard, Holmes (CR10) 2015; 66 Freeman, Hutton, Barnes, Zhu, Owens, Garber, Go, Hlatky, Heidenreich, Wang, Al-Ahmad, Turakhia (CR11) 2016; 9 G Hindricks (1943_CR3) 2020; 42 SM Singh (1943_CR8) 2013; 127 A Micieli (1943_CR6) 2016; 36 JV Freeman (1943_CR11) 2016; 9 PA Wolf (1943_CR2) 1991; 22 E Nédellec (1943_CR5) 2018; 16 VY Reddy (1943_CR7) 2016; 18 CT January (1943_CR4) 2019; 74 J Saw (1943_CR12) 2016; 32 VWY Lee (1943_CR9) 2016; 16 VY Reddy (1943_CR10) 2015; 66 AS Go (1943_CR1) 2001; 285 |
References_xml | – volume: 22 start-page: 983 year: 1991 end-page: 988 ident: CR2 article-title: Atrial fibrillation as an independent risk factor for stroke: the Framingham Study publication-title: Stroke doi: 10.1161/01.STR.22.8.983 – volume: 42 start-page: 373 year: 2020 end-page: 498 ident: CR3 article-title: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC publication-title: Eur Heart J doi: 10.1093/eurheartj/ehaa612 – volume: 9 start-page: 3407 year: 2016 ident: CR11 article-title: Costeffectiveness of percutaneous closure of the left atrial appendage in atrial fibrillation based on results from PROTECT AF versus PREVAIL publication-title: Circ Arrhythm Electrophysiol doi: 10.1161/CIRCEP.115.003407 – volume: 32 start-page: 1355.e9 year: 2016 end-page: 1355.e14 ident: CR12 article-title: Cost-effectiveness of left atrial appendage closure for stroke prevention in atrial fibrillation patients with contraindications to anticoagulation publication-title: Can J Cardiol doi: 10.1016/j.cjca.2016.02.056 – volume: 74 start-page: 104 year: 2019 end-page: 132 ident: CR4 article-title: AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2019.01.011 – volume: 66 start-page: 2728 year: 2015 end-page: 2739 ident: CR10 article-title: Time to cost-effectiveness following stroke reduction strategies in AF: warfarin versus NOACs versus LAA closure publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2015.09.084 – volume: 285 start-page: 2370 year: 2001 end-page: 2375 ident: CR1 article-title: revalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study publication-title: JAMA doi: 10.1001/jama.285.18.2370 – volume: 36 start-page: 366 year: 2016 end-page: 374 ident: CR6 article-title: A decision analysis of percutaneous left atrial appendage occlusion relative to novel and traditional oral anticoagulation for stroke prevention in patients with new-onset atrial fibrillation publication-title: Med Decis Mak doi: 10.1177/0272989X15593083 – volume: 16 start-page: 167 year: 2016 ident: CR9 article-title: Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation publication-title: BMC Cardiovasc Disord doi: 10.1186/s12872-016-0351-y – volume: 16 start-page: 793 year: 2018 end-page: 802 ident: CR5 article-title: Level of evidence in economic evaluations of left atrial appendage closure devices: a systematic review publication-title: Appl Health Econ Health Policy doi: 10.1007/s40258-018-0429-z – volume: 18 start-page: 979 year: 2016 end-page: 986 ident: CR7 article-title: Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin publication-title: Europace doi: 10.1093/europace/euv412 – volume: 127 start-page: 2414 year: 2013 end-page: 2423 ident: CR8 article-title: Economic evaluation of percutaneous left atrial appendage occlusion, dabigatran, and warfarin for stroke prevention in patients with nonvalvular atrial fibrillation publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.112.000920 – volume: 127 start-page: 2414 year: 2013 ident: 1943_CR8 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.112.000920 – volume: 285 start-page: 2370 year: 2001 ident: 1943_CR1 publication-title: JAMA doi: 10.1001/jama.285.18.2370 – volume: 18 start-page: 979 year: 2016 ident: 1943_CR7 publication-title: Europace doi: 10.1093/europace/euv412 – volume: 16 start-page: 167 year: 2016 ident: 1943_CR9 publication-title: BMC Cardiovasc Disord doi: 10.1186/s12872-016-0351-y – volume: 66 start-page: 2728 year: 2015 ident: 1943_CR10 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2015.09.084 – volume: 22 start-page: 983 year: 1991 ident: 1943_CR2 publication-title: Stroke doi: 10.1161/01.STR.22.8.983 – volume: 16 start-page: 793 year: 2018 ident: 1943_CR5 publication-title: Appl Health Econ Health Policy doi: 10.1007/s40258-018-0429-z – volume: 36 start-page: 366 year: 2016 ident: 1943_CR6 publication-title: Med Decis Mak doi: 10.1177/0272989X15593083 – volume: 32 start-page: 1355.e9 year: 2016 ident: 1943_CR12 publication-title: Can J Cardiol doi: 10.1016/j.cjca.2016.02.056 – volume: 42 start-page: 373 year: 2020 ident: 1943_CR3 publication-title: Eur Heart J doi: 10.1093/eurheartj/ehaa612 – volume: 74 start-page: 104 year: 2019 ident: 1943_CR4 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2019.01.011 – volume: 9 start-page: 3407 year: 2016 ident: 1943_CR11 publication-title: Circ Arrhythm Electrophysiol doi: 10.1161/CIRCEP.115.003407 |
SSID | ssj0051034 |
Score | 2.3144016 |
Snippet | Aims
To report hospitalization costs of patients with non-valvular atrial fibrillation (AF) submitted to percutaneous left atrial appendage closure (LAAC) with... To report hospitalization costs of patients with non-valvular atrial fibrillation (AF) submitted to percutaneous left atrial appendage closure (LAAC) with the... AimsTo report hospitalization costs of patients with non-valvular atrial fibrillation (AF) submitted to percutaneous left atrial appendage closure (LAAC) with... |
SourceID | proquest pubmed crossref springer |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 105 |
SubjectTerms | Aged Atrial Appendage - surgery Atrial Fibrillation - mortality Atrial Fibrillation - surgery Cardiac arrhythmia Cardiac Catheterization Cardiology Cost analysis Costs Costs and Cost Analysis Female Fibrillation Germany Hospitalization Hospitalization - economics Humans Male Medicine Medicine & Public Health Mortality Original Paper Patients Prostheses and Implants - economics Regression analysis Risk assessment Survival |
SummonAdditionalLinks | – databaseName: SpringerLINK - Czech Republic Consortium dbid: AGYKE link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LT9wwEB61i1T10ieFbWnlStzAKJvY8eaIKihqgRMrwSmy47GQ2M0iklUlfj0zeSEKrcQ5juN47JlvPDOfAbYLn0wCWUYZOVRShchKZzFIshY2tpowcyPpk9P0aKZ-nevzriis6rPd-5Bko6mHYjcuI40lpxQQLFGJNC9hTbODMoK1_Z8Xvw96DcwkcU00eZpyVs9UdcUyT_fy0CA9QpmPIqSN4Tl8C7N-yG2-ydXeqnZ7xe1fbI7P_ad38KZDomK_XTrv4QWWH-DVSRdr_wjFMYZa2OZaD2Gv-a5c0j2imC_5UFHwAa4g9Cj-kDK_XNhSeGStI26YDBar_s3ANQXzNuNOLIZkG1Esq7pah9nhwdmPI9ldySCLxOhamjQzGgmVoQvaxqnxGSJhQD9FwpnkGkWxL5yLrbeE23QaPLmXkQ8mMBGltsknGJXLEjdBOGVUZiPrs8wqg8FNMaSW_FGFpEMwjGHSyyUvOr5yvjZjng9My83s5TR7eTN7uRnDzvDOdcvW8d_WW724827nVjkT9GeE07LJGL4Pj2nPcSDFlrhcURuONTJPfzSGjXaZDJ9LVKpjHVPnu73I7zv_91g-P6_5F3gdcx1Gcxa0BaP6ZoVfCR3V7lu3Ge4AVHADbg priority: 102 providerName: Springer Nature |
Title | Left atrial appendage closure with the watchman device reduces atrial fibrillation management costs |
URI | https://link.springer.com/article/10.1007/s00392-021-01943-7 https://www.ncbi.nlm.nih.gov/pubmed/34652527 https://www.proquest.com/docview/2620906491 https://www.proquest.com/docview/2582807890 |
Volume | 111 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swED_aBMZexr6XfgQN9raJObJsxQ-jNCNZ2dYwxgrZk5GtE3tI7axx6b_fO8V2GWV98oMl2eiku590d78DeFe6eOLJMsqoQC21j6wsLHpJ1sIqmxBmDpI-X6ZnF_rrKlntwbLLheGwyk4nBkXt6pLvyD8ycXpG9jObnGz-Sq4axd7VroSGbUsruE-BYmwfhoqrKg9gOJsvf_zsdDPTxwU_8zTleJ-pbtNoQjIdp6kqySELBHt0LM2_puoe_rznOw0mafEUnrRYUpzuhP8M9rB6Do_OW2_5Cyi_o2-EDYU5hN1wtVvSHqJc13wtKPgKVhD-Ezekjv9c2ko4ZL0hrpjOFbddT89ZAetdzJy47MNlRFlvm-1LuFjMf30-k21RBVnGJmmkSTOTIOEqLHxiVWpchkgozk2RkCIdbiLlyqJQ1llCXknqHR0QI-eNZyrJxMavYFDVFb4BUWijMxtZl2VWG_TFFH1q6USpkbQA-hFMuvnLy5ZxnAtfrPOeKznMeU5znoc5z80I3vd9Nju-jQdbH3Viydu9t83vVsoI3vavadewK8RWWF9TG_YWMtN-NILXO3H2n4t1mqhE0eAfOvneDf7_fzl4-F8O4bHizIlwe3MEg-bqGo8JzzTFGPbNyoxheLqYzZb8_PL723zcLt1bVP30Dg |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VVgIuiDcLBYwEJ7DIOnayOVSIR6st3V0h1Eq9BScei8M2WZpUFX-O38aMN0mFKnrrOY4Tzdgznz0z3wC8Ll089uQZZVSgltpHVhYWvSRvYZU1hJmDpueLZHqkvx6b4w3409fCcFplbxODoXZ1yXfk75k4PSP_mY0_rH5J7hrF0dW-hYbtWiu4nUAx1hV2HODvczrCNTv7X0jfb5Ta2z38PJVdlwFZxqlpZZpkqUECGlh4Y1WSugyRYI2bIEEnQvuRcmVRKOssQRGTeEcnpsj51DO3orExzXsDtgh2xLSrtj7tLr59730B09WFuPYk4fyiie7KdkLxHpfFKskpEgSzdCzTf13jJbx7KVYbXODeXbjTYVfxcb3Y7sEGVvfh5ryLzj-Acoa-FTY0AhF2xd11yVqJclnzNaTgK19BeFOck_n_eWIr4ZDtlDhl-lhs-jc9VyEs1zl64mRIzxFl3bTNQzi6FvE-gs2qrvAJiEKnOrORdVlmdYq-mKBPLJ1gNZLVQT-CcS-_vOwYzrnRxjIfuJmDzHOSeR5knqcjeDu8s1rze1w5ertXS97t9Sa_WJkjeDU8pl3KoRdbYX1GYzg6ycz-0Qger9U5fC7WiVFG0eTvev1eTP7_f3l69b-8hFvTw_ksn-0vDp7BbcVVG-HmaBs229MzfE5Yqi1edAtWwI_r3iN_ASUzLKM |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIlVcEOW50IKR4ARWs44Tbw5VhSirlj7EgUp7C048FodtsjSpKv4av44Z51Ghit56ju1YM56Zz54XwLvSxVNPllFGBWqpfWRlYdFLshZW2YQwc-D0yWl6cKa_LpLFGvwZcmE4rHLQiUFRu7rkN_IdLpyekf3Mpju-D4v4tj_fW_2S3EGKPa1DO43uiBzh7yu6vjW7h_vE6_dKzb98_3wg-w4DsoxN0kqTZiZBAhlY-MSq1LgMkSCNmyHBJkL6kXJlUSjrLMGQJPWObkuR88ZzXcXExrTuPbhvYjLrJEtmMV72uFBd8GjPUo4smuk-YSek7XFCrJIcHEEAS8fS_GsUbyDdG17aYPzmj-Bhj1rFp-6YbcIaVo9h46T3yz-B8hh9K2xoASLsivvqkp4S5bLmB0jBj72CkKa4IsX_89xWwiFrKHHBhWOxGWZ6zj9YdtF54nwMzBFl3bTNUzi7E-I-g_WqrvAFiEIbndnIuiyz2qAvZuhTS3dXjaRv0E9gOtAvL_va5txiY5mPVZkDzXOieR5onpsJfBjnrLrKHreO3hrYkvdS3uTXZ3ICb8fPJJ_sdLEV1pc0hv2SXNM_msDzjp3j72KdJipRtPjHgb_Xi_9_Ly9v38sb2CDJyI8PT49ewQPF6RrhyWgL1tuLS9wmENUWr8NpFfDjrsXjL90tKj8 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Left+atrial+appendage+closure+with+the+watchman+device+reduces+atrial+fibrillation+management+costs&rft.jtitle=Clinical+research+in+cardiology&rft.au=D+Ancona%2C+Giuseppe&rft.au=Safak%2C+Erdal&rft.au=Weber%2C+Denise&rft.au=Arslan%2C+Fatih&rft.date=2022-01-01&rft.issn=1861-0692&rft.eissn=1861-0692&rft.volume=111&rft.issue=1&rft.spage=105&rft_id=info:doi/10.1007%2Fs00392-021-01943-7&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1861-0684&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1861-0684&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1861-0684&client=summon |